A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
for Gastroesophageal-junction Cancer
29 locations incl. Anaheim
Sponsor: Shanghai Henlius Biotech
Sex: All·Age: 18+
Code: NCT06532006·Phase 3·Recruiting·Listed Aug 2024